Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Inclusion Criteria:

• Histology diagnoses epithelial ovarian, primary peritoneal, or fallopian tube(Stage II, III or IV)either optimal or suboptimal after initial surgery.

  • All patients must have had appropriate surgery for ovarian, peritoneal, or fallopian tube carcinoma with tissue available for histologic evaluation
  • Histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant brenner tumor, adenocarcinoma NOS.
• GOG(Gynecologic Oncology Group)performance status of 0,1,2
• Entered within 12 weeks of most recent surgery performed for diagnosis.
• Patients must have adequate bone marrow function, renal function,hepatic function, neurologic function, blood coagulation parameters within normal limits
• Sign approved consent form.

Exclusion Criteria:

• Patients who have received prior treatment other than initial surgery
• Patients who have received prior radiotherapy to any portion of their abdominal cavity or pelvis
• Patients with acute hepatitis or active infection
• Patients with active bleeding
• Patients with unstable angina
• Patients with history of invasive malignancies with the exception of nonmelanoma skin cancer and localized breast cancer.
• Patients who have received any target therapy or hormonal therapy for management of their ovarian cancer.
• Patients with synchronous primary endometrial cancer.
• Patients with epithelial tumors of low malignant potential
• Serious non healing wound, ulcer or bone fracture.
• Patients with history or evidence of CNS(central nervous system disease)
• Patients under 18 years old.
• Patients who have received prior therapy with anti-VEGF(vascular endothelial growth factor)

drug, bevacizumab

• Patients who have a history of allergic reaction to polysorbate 80.